OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of “Hold” from Brokerages

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) have been assigned an average recommendation of “Hold” from the five brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $6.3333.

OKYO has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of OKYO Pharma in a research note on Thursday, January 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a research note on Tuesday, April 21st. Finally, Piper Sandler initiated coverage on OKYO Pharma in a research note on Friday, February 20th. They set an “overweight” rating and a $7.00 target price for the company.

OKYO Pharma Price Performance

NASDAQ OKYO opened at $1.63 on Wednesday. The business has a 50 day simple moving average of $1.62 and a 200 day simple moving average of $1.98. OKYO Pharma has a one year low of $1.32 and a one year high of $3.35.

Institutional Investors Weigh In On OKYO Pharma

Several large investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new stake in OKYO Pharma during the third quarter worth approximately $31,000. XTX Topco Ltd bought a new position in OKYO Pharma in the fourth quarter worth approximately $36,000. Finally, Renaissance Technologies LLC boosted its holdings in OKYO Pharma by 235.0% in the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after acquiring an additional 96,800 shares in the last quarter. Institutional investors and hedge funds own 2.97% of the company’s stock.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.